Attitudes towards open-label versus placebo-control designs in oncology randomized trials: A survey of medical oncologists.
Igal KushnirMark J ClemonsDean FergussonDominick BosséMartin Neil ReaumePublished in: Journal of evaluation in clinical practice (2022)
Canadian medical oncologists participating in this survey are divided in their opinions regarding the acceptability of an open-label design in randomized-controlled trials, where no standard therapy is approved. Clearer guidance from regulatory bodies on the adequacy of different trial designs is needed.